Eli Lilly Commits Over $1 Billion to Expand India Manufacturing Footprint

Eli Lilly & Co. plans to invest over $1 billion in India over the next several years to boost its contract manufacturing operations1 2 5.

The investment will support increased production and supply for Lilly’s key drugs, including those for diabetes, obesity, Alzheimer’s, cancer, and autoimmune conditions2.

A new Manufacturing & Quality Center will be established in Hyderabad, serving as a technical and oversight hub for Lilly’s India-based manufacturing network4 6.

Lilly will hire engineers, scientists, chemists, quality control professionals, and managers as it scales operations in India4 6.

This move is part of a broader strategy to build global supply chain resilience and leverage India’s skilled workforce and advanced pharmaceutical infrastructure2 4.

Lilly currently does not operate its own manufacturing plant in India but is actively engaging with local contract manufacturers2.

The announcement follows the recent launch of Lilly’s weight-loss drug Mounjaro in India and comes as global pharma companies reassess manufacturing strategies in response to new US tariffs on imported drugs2 4.